Wednesday, November 25, 2009, 10:30am EST - Canadian Markets close in 5 hours and 30 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Martek Biosciences Corp. (MATK)

At 10:13 EST: 18.055 USD  Up 0.005 (0.03%)  
MORE ON MATK
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Martek Biosciences Corporation (NasdaqNM:MATK) Delayed quote dataEdit
Last Trade: 18.055 USD
Trade Time: 10:13AM EST
Change: Up 0.005 (0.03%)
Prev Close: 18.05
Open: 17.97
Bid: 18.05 x 800
Ask: 18.07 x 200
1y Target Est: 31.83
Day's Range: 17.91 - 18.17
52wk Range: 15.36 - 31.35
Volume: 33,542
Avg Vol (3m): 318,215
Market Cap: 600.13M
P/E (ttm): 18.39
EPS (ttm): 0.982
Div & Yield: N/A (N/A%)
Martek Biosciences Corp. (MATK)
1d  5d  3m  6m  1y  2y  5y  max 
 Add MATK to Portfolio   Download Data

HEADLINES
Lightning Round OT: Martek Biosciences, Valmont Industries and More
at CNBC (Thu, Nov 19)
Algae Biofuels Have a Promising Future
at Seeking Alpha (Fri, Nov 13)
Martek Biosciences: Can It Turn Algae into Gold, or at the Least Oil?
at Seeking Alpha (Fri, Oct 30)
Neurogenic Orthostatic Hypotension Treatment Should Pass Phase III Trials: Catalyst For Biotech Stock Says Wedbush Morgan Analyst
Wall Street Transcript (Tue, Oct 20)
Martek's life'sDHA(TM) Featured in New Nutrioli DHA Cooking Oil from Ragasa
PRNewswire (Mon, Sep 21)
MARTEK BIOSCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Fri, Sep 18)
MARTEK BIOSCIENCES CORP Financials
EDGAR Online Financials (Thu, Sep 17)
Martek Announces Addition to Its Board of Directors
PRNewswire (Wed, Sep 16)
Martek to Present at Two Upcoming Investor Conferences
PRNewswire (Tue, Sep 15)
Martek Announces Settlement of Patent Dispute with Capsugel France Capsugel to Purchase DHA from Martek
PRNewswire (Thu, Sep 10)
MARTEK BIOSCIENCES CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online (Wed, Sep 9)
Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case Martek Wins on All Counts Against Lonza
PRNewswire (Tue, Sep 8)
More Headlines for MATK...

ANALYST
EPS Est (next year) (Oct-08) : 0.94
EPS Est (in 2 years) (Oct-09) : 1.12
Avg Rec (current)*: 2.8
PEG Ratio: 1.32
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Martek Biosciences Corporation engages in the development and commercialization of novel products from microalgae, fungi, and other microbes primarily in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News Canadian Indices